UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/600/0.1/19.03.25 | Market Closed - Börse Stuttgart 02:39:14 2024-05-24 pm EDT | ||
| 1.12 EUR | +15.46% |
|
| Current month | +180.00% | ||
| 1 month | +107.41% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-05-24 | 1.12 | +15.46% |
| 24-05-23 | 0.97 | +6.59% |
| 24-05-22 | 0.91 | +4.60% |
| 24-05-21 | 0.87 | -14.71% |
| 24-05-20 | 1.02 | +10.87% |
Delayed Quote Börse Stuttgart
Last update May 24, 2024 at 02:39 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HD441Z |
| ISIN | DE000HD441Z2 |
| Date issued | 2024-03-25 |
| Strike | 600 $ |
| Maturity | 2025-03-19 (298 Days) |
| Parity | 10 : 1 |
| Emission price | 0.88 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.15 € |
|---|---|
| Lowest since issue | 0.32 € |
| Spread | 0.05 € |
| Spread % | 4.27% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
457
USD
Average target price
462.8
USD
Spread / Average Target
+1.28%
- Stock Market
- Warrants
- Warrant
